Modulation of KCNQ potassium channel activity for treatment of psychiatric disorders and the symptoms thereof

Details for Australian Patent Application No. 2010256541 (hide)

Owner Marquette University

Inventors Ghasemzadeh, Mohammad Hossein Behnam

Agent Freehills

Pub. Number AU-A-2010256541

PCT Pub. Number WO2010/141712

Priority 61/217,706 03.06.09 US

Filing date 3 June 2010

Wipo publication date 9 December 2010

International Classifications

A61K 31/4427 (2006.01) - containing further heterocyclic ring systems

A61K 31/122 (2006.01) - having the oxygen atom directly attached to a ring, e.g. quinones, vitamin K, anthralin

A61K 31/4025 (2006.01) - not condensed and containing further heterocyclic rings, e.g. cromakalim

A61K 31/4725 (2006.01)

A61P 25/00 (2006.01) Drugs for disorders of the nervous system

A61P 25/18 (2006.01) Drugs for disorders of the nervous system

Event Publications

8 December 2011 PCT application entered the National Phase

  PCT publication WO2010/141712 Priority application(s): WO2010/141712

15 December 2011 Amendment Made

  The nature of the amendment is as shown in the statement(s) filed 16 Nov 2011

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2010256543-Systems and methods for creating virtual universal plug-and-play systems

2010256533-Imaging of myelin basic protein